Qiagen NV (QGEN)

27.81
0.17 0.62
NASDAQ : Services
Prev Close 27.64
Open 27.81
Day Low/High 27.80 / 27.89
52 Wk Low/High 19.94 / 28.53
Volume 44.24K
Avg Volume 911.20K
Exchange NASDAQ
Shares Outstanding 234.25M
Market Cap 6.49B
EPS 0.50
P/E Ratio 51.28
Div & Yield N.A. (N.A)

Latest News

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

QIAGEN Enhances Bioinformatics Portfolio With Acquisition Of OmicSoft

Powerful multi-omics data management solution and highly curated 'omics' data sets complement QIAGEN's industry-leading interpretation solutions

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

QIAGEN Announces Comprehensive Range Of Enhancements For GeneReader NGS System

Launch of new QIAact gene panels and customized panels service complemented by performance upgrades that further differentiate first Sample to Insight NGS sequencing solution

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

QIAGEN Submits QuantiFERON®-TB Gold Plus For U.S. Regulatory Approval

U.S. submission builds on 2016 launch of fourth-generation test in more than 60 countries and already used in more than 600,000 people to date

QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines From U.S. Professional Societies

QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines From U.S. Professional Societies

New guidelines recommend broader use of modern blood TB tests like QuantiFERON-TB Gold over the 100-year-old tuberculin skin test

QIAGEN's GeneReader NGS System Streamlines Data Management For Labs

QIAGEN's GeneReader NGS System Streamlines Data Management For Labs

New middleware co-developed with Genohm ensures full chain of custody from Sample to Insight and integrates with most LIMS systems

QIAGEN GeneReader NGS System To Relaunch In U.S. Market

QIAGEN GeneReader NGS System To Relaunch In U.S. Market

New improved chemistry for first Sample to Insight next-generation sequencing solution to be made available to first customers in December 2016

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment to shareholders expected to be completed in January 2017

QIAGEN Launches QIAscout For Single-cell Isolation

QIAGEN Launches QIAscout For Single-cell Isolation

Compact, versatile and yet very affordable instrument provides unique front-end in workflows for molecular analysis of individual cells

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.

QIAGEN Unveils Unique Sample To Insight Solutions For Liquid Biopsies And Hereditary Diseases

QIAGEN Unveils Unique Sample To Insight Solutions For Liquid Biopsies And Hereditary Diseases

All-in-One library prep kit, plus collection, stabilization and bioinformatics solutions enable NIPT and cancer research

QIAGEN Launches High-throughput Solutions For Human ID Databases

QIAGEN Launches High-throughput Solutions For Human ID Databases

Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting

QIAGEN Announces Plans To Return Approximately $250 Million To Shareholders Via Synthetic Share Repurchase Proposal

QIAGEN Announces Plans To Return Approximately $250 Million To Shareholders Via Synthetic Share Repurchase Proposal

Proposal would adjust capital structure through 4% reduction in number of shares outstanding and direct capital repayment to shareholders

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEUA, BPMC, CAA, CAT, COMM, DAIO, DKS, EFII, HDS, HOG, ISTR, KEM, MSCC, MT, NWHM, QGEN, QLYS, TPRE Downgrades: COHU, DMD, EMN, GRC, SFS, SYNA, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Diversified Services Stocks Nudging The Industry Higher

3 Diversified Services Stocks Nudging The Industry Higher

TheStreet highlights 3 stocks pushing the diversified services industry higher today.

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) stock is jumping on Friday morning after the company posted earnings and revenue that topped analysts’ projections for the 2016 second quarter.

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Trade-Ideas LLC identified Qiagen (QGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

QIAGEN Launches

QIAGEN Launches "Digital NGS" Solutions With Unique Molecular Index Technology To Reliably Detect All Genetic Variation

QIAseq Targeted NGS panels deliver highly sensitive, unbiased and accurate NGS insights

Buy These 5 Stocks This Week for Breakout Gains

Buy These 5 Stocks This Week for Breakout Gains

These five technical setups are showing solid upside potential right now.

QIAGEN Announces Successful Completion Of Tender Offer For Shares In Exiqon

QIAGEN Announces Successful Completion Of Tender Offer For Shares In Exiqon

Transaction will enhance leadership position in RNA solutions from Sample to Insight

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.